Objective : To evaluate the clinical efficacy and safety of Qiangxin concentrated decoction combined with conventional western medicine in the treatment of patients with heart water disease (syndrome of yang deficiency and water flooding). Methods : A total of 81 patients from April 2024 to June 2025 were enrolled and randomly divided into the experimental group (treated with Qiangxin concentrated decoction+conventional treatment) and the control group (treated with conventional treatment). The treatment course lasted for 2 weeks. The TCM syndrome scores, cardiac function indicators (left ventricular ejection fraction LVEF, brain natriuretic peptide BNP), degree of edema and safety indicators were observed. Results : The total effective rate in the experimental group was 85.37%, which was significantly higher than that in the control group (60.00%) (P<0.05). The improvement in LVEF (47.49±4.18% vs 44.88±6.07%), the cardiac function classification (2.90±0.37 vs 3.10±0.38), the 6MWT (337.39±65.14m vs 304.98±60.59m), and the decrease in NT-proBNP (5905.66±3827.84 vs 11067.53±6898.61pg/mL) were all superior to those in the control group (P<0.05). No serious adverse reactions occurred. Conclusion : Qiangxin concentrated decoction can effectively improve the cardiac function and edema symptoms of patients with heart water disease of the syndrome of yang deficiency and water flooding, and has good safety.
Yongqiang He (Fri,) studied this question.